1
Narasinga Rao, Morten Meldal, Klaus Bock, Ole Hindsgaul: Library of glyco-peptides useful for identification of cell adhesion inhibitors. Glycomed Corporation, Lyon & Lyon, August 18, 1998: US05795958 (115 worldwide citation)

Glycopeptides having the following structure are described: ##STR1## wherein: X.sub.1 is hydrogen, an acetyl group, an acyl group or amino acid; R is .alpha.-L-fucose, .alpha.-D-fucose, .beta.-L-fucose or .beta.-D-fucose, wherein R is O-glucosidically linked to A.sub.1 ; A.sub.1 is serine, threonine ...


2
Miao Zenwei, Sun Ying, Wu Frank, Nakajima Suanne, Xu Guoyou, Or Yat Sun, Wang Zhe: Macrocyclic hepatitis c serine protease inhibitors. Enanta Pharmaceuticals, Miao Zenwei, Sun Ying, Wu Frank, Nakajima Suanne, Xu Guoyou, Or Yat Sun, Wang Zhe, HSI Jeffrey D, August 26, 2004: WO/2004/072243 (113 worldwide citation)

The present invention relates to compounds of Formula (I, II or III), or a pharmaceutically acceptable salt, ester, or prodrug, thereof: (I), (II), (III), wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity o ...


3

4
Holloway M Katharine, Liverton Nigel J, Mccauley John A, Rudd Michael T, Vacca Joseph P, Ludmerer Steven W, Olsen David B: Macrocyclic peptides as hcv ns3 protease inhibitors. Merck & Co, Holloway M Katharine, Liverton Nigel J, Mccauley John A, Rudd Michael T, Vacca Joseph P, Ludmerer Steven W, Olsen David B, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, February 8, 2007: WO/2007/016441 (82 worldwide citation)

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. Formula (I).


5
Ripka Amy, Campbell Jeffrey Allen, Good Andrew Charles, Scola Paul Michael, Sin Ny, Venables Brian: Hepatitis c virus inhibitors. Bristol Myers Squibb Company, Ripka Amy, Campbell Jeffrey Allen, Good Andrew Charles, Scola Paul Michael, Sin Ny, Venables Brian, VOLLES Warren K, April 22, 2004: WO/2004/032827 (82 worldwide citation)

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in t ...


6
Mark A Findeis, Malcolm L Gefter, Gary Musso, Ethan R Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung Ja Lee, Michael Kelley, Sonja Komar Panicucci, Christopher C Arico Muendel, Kathryn Phillips, Neil J Hayward: Modulators of &bgr;-amyloid peptide aggregation comprising D-amino acids. Praecis Pharmaceuticals, Giulio A DeConti Jr, Maria C Laccotripe, Lahive & Cockfield, October 16, 2001: US06303567 (81 worldwide citation)

Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at le ...


7
Crescenzi Benedetta, Donghi Monica, Ferrara Marco, Gardelli Cristina, Harper Steven, Koch Uwe, Rowley Michael, Summa Vincenzo: Macrocyclic compounds as antiviral agents. Istituto Di Ricerche Di Biologia Molecolare P Angeletti, Crescenzi Benedetta, Donghi Monica, Ferrara Marco, Gardelli Cristina, Harper Steven, Koch Uwe, Rowley Michael, Summa Vincenzo, MAN Jocelyn, December 27, 2007: WO/2007/148135 (78 worldwide citation)

The present invention relates to macrocyclic compounds of formula (I): wherein W, n, m, R1, R2, R3, R4, R5, Ra, M, Z and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical co mposit ions comprising them, and their use for the treatment or prevention of infection ...


8

9
Gesellchen Paul David, Shuman Robert Theodore: Tripeptide antithrombotic agents.. Lilly Co Eli, April 8, 1992: EP0479489-A2 (78 worldwide citation)

Thrombin inhibitors represented by the formula as provided wherein A(C=O)- is, inter alia, phenylglycyl, cyclohexylglycyl, cyclohexenylglycyl, thienylglycyl or naphthylglycyl, wherein the alpha -amino group is preferably substituted by alkyl e.g. methyl or an alkoxycarbonyl, cycloalkoxycarbonyl or a ...


10